Maplight Therapeutics (NASDAQ:MPLT) Shares Down 10% – Should You Sell?

Posted by Brenda Bartman on May 18th, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) dropped 10% on Monday . The company traded as low as $26.20 and last traded at $25.8550. Approximately 257,648 shares traded hands during mid-day trading, an increase of 10% from the average daily volume of 233,663 shares. The stock had previously closed at $28.73.

Analysts Set New Price Targets

A number of analysts recently commented on the company. HC Wainwright initiated coverage on Maplight Therapeutics in a research note on Monday, May 4th. They set a “buy” rating and a $45.00 price objective on the stock. Needham & Company LLC started coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price on the stock. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Lifesci Capital upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a report on Thursday. Finally, Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Maplight Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.

Check Out Our Latest Stock Report on Maplight Therapeutics

Maplight Therapeutics Stock Down 7.7%

The business’s 50 day simple moving average is $24.24. The firm has a market cap of $1.13 billion and a PE ratio of -0.67.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). As a group, analysts expect that Maplight Therapeutics, Inc. will post -4.04 earnings per share for the current year.

Insider Activity at Maplight Therapeutics

In related news, CEO Christopher A. Kroeger sold 13,980 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $30.11, for a total transaction of $420,937.80. Following the completion of the transaction, the chief executive officer owned 1,512,329 shares of the company’s stock, valued at approximately $45,536,226.19. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vishwas Setia sold 10,564 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $28.24, for a total transaction of $298,327.36. Following the transaction, the chief financial officer directly owned 356,256 shares in the company, valued at approximately $10,060,669.44. This represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have bought 25,000 shares of company stock valued at $441,168 and have sold 391,204 shares valued at $11,125,068. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maplight Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Strs Ohio acquired a new stake in Maplight Therapeutics during the fourth quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at about $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at about $93,000. MetLife Investment Management LLC purchased a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics during the 4th quarter worth approximately $205,000.

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.